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Abstract
Breast cancer is the most commonly diagnosed form of cancer among women living in
the United States, and it is characterized by uncontrolled cell growth in either the lobules or
ducts of the breast tissue. Additionally, breast cancer accounts for the second highest number of
cancer deaths, only trailing behind lung cancer. Current efforts to treat this form of cancer
include various combinations of chemotherapy, mastectomy, radiation, and endocrine therapy;
however, there is still a need for treatments with increased selectivity. Use of the CRISPR/Cas9
gene-editing tool is a method that could be used to directly target cancer cells. This gene-editing
tool is guided to the appropriate sequence through a complementary small guide RNA (sgRNA)
that can be designed for any gene of interest. Angiogenesis, which is required in order for tumor
cells to survive, is the process in which new blood vessels are formed from pre-existing vessels,
and angiomotin (Amot) is directly involved in this process. Additionally, various studies have
found that Amot enables the proliferation of mammary epithelia through the activation of
extracellular signal-regulated kinases (ERK1/2). Therefore, Amot is thought to be a putative
oncogene involved in breast cancer. The current study focused on reducing Amot expression in
tumorigenic MDA-MB-468 cells via CRISPR. Cancer cells were transfected with varying guide
RNA (gRNA) sequences and varying concentrations of CRISPR-containing DNA constructs.
qPCR data suggested that the gRNA sequence “Amot 174” was most effective at reducing Amot
mRNA transcripts. Amot mRNA reduction correlated with a decrease in proliferating cell
nuclear antigen (PCNA) mRNA transcripts, suggesting a decrease in cell viability. Follow up
studies will include Western blotting to confirm reduction in Amot protein, cell viability assays
to confirm cytotoxicity, and end-point PCR to confirm editing of the Amot gene.
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Introduction
A Brief Overview of Cancer
Cancer is a disease that has become the leading cause of death in developed nations.
Cancer can impact individuals across all demographics. Each year in the United States, 1 million
people are diagnosed with cancer, and 500,000 die from this disease (Klug et al. 2015). The
disease of cancer is distinguished by two major characteristics: proliferation and metastasis.
Normally, the tendency for cells to proliferate is not a problem; cells need to divide in order to
replace dead or damaged cells. However, the proliferation of cancer cells is continuous and does
not respond to the normal regulatory signals of the cell cycle (Figure 1). The cell cycle consists

Figure 1: Cell cycle phases and checkpoints (Klug et al. 2015).
of five stages: G1, G0, S, G2, and M. Interphase is the broad term that encompasses the G1, G0,
S, and G2 phases, and this is the phase in which the cell spends most of its time. The M phase,

1

on the other hand, is rapid and is known as mitosis. The G1 phase is characterized by the growth
of the cell and preparation for the DNA synthesis stage, called S phase. The G0 phase is a
quiescent stage in which the cell remains metabolically active but does not divide; cells enter this
phase when they are mature and receive signals to halt growth. In the S phase, the chromosomal
DNA is duplicated in order to provide equal genetic material for each daughter cell. During the
G2 phase, the cell continues to grow. Finally, in the M phase, the cell divides and produces two
identical daughter cells. (Klug et al. 2015). It is whether or not the mature cell is able to remain
in the G0 phase at the appropriate time that determines if a cell becomes cancerous. For example,
if a tissue does not need to grow, then the cells need to remain in the G0 phase. However, cancer
cells do not enter this quiescent phase and continue to proliferate. Proliferation is detrimental to
the proper functioning of the organ in which the cancer cells originated. Metastasis, on the other
hand, is the tendency for cancer cells to migrate to other organs of the body, and it is deeply
problematic for the patient (Klug et al. 2015). The cancerous cells not only move to a new
location, but they also spread the cancerous phenotype to the new locations. Cancer can occur in
any organ of the body, and it is breast cancer that is of particular interest in the current study.

Breast Cancer Types and Prevalence
Prior to distinguishing the differing types of breast cancer, it is first important to
understand the basic anatomy and physiology of the human breast. The breast of the human
female is a specialized organ that enables the production of milk during lactation. The breast
tissue consists of epithelial lobules, in which the milk is generated, and epithelial ducts that
connect the lobules to the nipple (Overview of the Breast - Breast Pathology 2020). The lobules
and ducts of the human breast are usually the components of epithelial tissue that are implicated
in the development of cancer. The various lobules and ducts (Figure 2) are surrounded by the
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Figure 2: The anatomy of the human breast (Overview of the Breast - Breast Pathology 2020).
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fibrous and adipose tissues that make up a large portion of the breast. The breast is positioned on
top of the pectoralis muscle of the chest, and breast tissue traverses the distance between the
sternum and axilla. The portion of breast tissue that reaches the axilla is known as “the axillary
tail of Spence.” The structure of the male breast is largely similar to the female breast, except for
the fact that the male breast lacks the lobules that are able to produce milk. Blood supply to this
organ is provided by the internal mammary artery, and the lymphatic fluid from the breast tissue
flows to lymph nodes located in the axilla (Overview of the Breast - Breast Pathology 2020).
Given the general anatomy of the human breast, it is much easier to delineate which structures
are involved in the differing types of breast cancer. For example, there are two main types of
breast cancer: ductal carcinoma and lobular carcinoma. As discussed earlier, the epithelial ducts
are those tubes that connect the milk-producing lobules to the nipple. Therefore, ductal
carcinoma is characterized by cancer cells that occur in these epithelial ducts. Within the
category of ductal carcinoma, there is the classification of invasive ductal carcinoma (IDC) and
the classification of ductal carcinoma in situ (DCIS). Ductal carcinoma in situ is a non-invasive
type of breast cancer; therefore, this type of breast cancer is not life-threatening. In most cases,
the tumor can be surgically removed. However, those who are diagnosed with DCIS have an
elevated risk of being diagnosed with IDC later on in life (BreastCancer.org 2018). The category
of invasive ductal carcinoma, on the other hand, is potentially life-threatening due to the fact that
these cancerous cells are able to invade the surrounding tissues of the breast and the lymph nodes
of the axilla. There are many different subtypes of invasive ductal carcinomas, such as tubular
carcinoma, medullary carcinoma, mucinous carcinoma, papillary carcinoma, and cribriform
carcinoma. Tubular carcinoma is characterized by the formation of small, tubular tumors. Given
the slow-growing nature of these tumors, this subtype of IDC is considered to be responsive to
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treatment and less aggressive than other subtypes (BreastCancer.org 2018). The medullary
subtype forms tumors that are soft and fleshy in appearance; these tumors are also slow-growing
and do not usually spread to the lymph nodes. The medullary subtype is relatively rare, and it has
been associated with the BRCA1 mutation (BreastCancer.org 2018). Mucinous carcinoma is
distinguished by its tumors that consist of cancer cells that are immersed in a collection of
mucin, which is a component of mucus. There seems to be a trend in which diagnoses of
mucinous carcinoma are more prevalent in women that have already gone through menopause. It
is also important to mention that this subtype is also not very aggressive in nature
(BreastCancer.org 2018). The tumors of invasive papillary carcinomas have a definitive border
and fingerlike projections, and they are moderate in terms of growth rate of tumors
(BreastCancer.org 2018). Lastly, cribriform invasive ductal carcinoma is characterized by tumors
in the connective tissues of the breast; these tumors form between the lobules and the ducts, and
they are recognizable by “holes” in between the cells of the tumor (BreastCancer.org 2018). The
entire category of invasive ductal carcinoma, which consists of all the aforementioned subtypes,
is the most common type of breast cancer, making up about 80 percent of all breast cancer
diagnoses (BreastCancer.org 2018). The second category of breast cancer, invasive lobular
carcinoma, is also the second most common type of breast cancer. In lobular carcinoma, the
tumor originates in the lobules of the breast, and the cancerous cells migrate throughout the
surrounding breast tissues as well as into the lymph nodes (BreastCancer.org 2018). Given the
plethora of subtypes of breast cancer, it is therefore reasonable that breast cancer is the most
commonly diagnosed cancer among women in the United States, accounting for about 1 in 3
cancer diagnoses in women. Given the high prevalence in the population, breast cancer is the
second highest cause of cancer death, only trailing behind lung cancer (DeSantis et al. 2014). In
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the United States, there is a 1-in-8 likelihood that a woman will be diagnosed with breast cancer.
This is an increase from the previous likelihood of 1-in-11 in the 1970s. Some hypothesize that
this greater incidence for breast cancer may be due to both longer life expectancy, varying
reproductive behaviors (i.e., delayed childbearing and bearing fewer children), and the greater
use of mammography screening (DeSantis et al. 2014). Up until the 1990s, the incidence of
breast cancer seemed to be steadily rising. However, this increase began to level off in the 1990s.
Furthermore, in the early 2000s there was a drop of about 7% in breast cancer incidence.
Researchers believe that this drop was due to a decrease in the use of hormonal treatment for
menopause, which was shown to have an association with breast cancer development (DeSantis
et al. 2014). According to a particular study, breast cancer is the most frequently diagnosed
cancer and the leading cause of cancer death among females across the globe, demonstrating the
worldwide relevance of breast cancer (Jemal et al. 1999).

Various Treatments for Breast Cancer
Given the prevalence of breast cancer throughout the population, it is imperative that
effective treatment plans are established. There are several options that can be used to treat breast
cancer: surgical treatments, radiation, chemotherapy, endocrine therapy, and tissue-targeted
therapy. Often times, these treatment options are used in a variety of combinations depending on
the stage of the progression of the breast cancer, the type of breast cancer, and the age and preexisting conditions of the patient. Stage 0 breast cancer, for example, includes lobular carcinoma
in situ and ductal carcinoma in situ. For lobular carcinoma, no treatment is required, but the
patients with this type of breast cancer should undergo rigorous monitoring as well as pursue
preventative endocrine therapeutics, such as tamoxifen, if the cancer is positive for estrogen
receptors (Maughan et al. 2010). For ductal carcinoma in situ, the mass should be surgically
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removed with breast-conserving surgery and treated with radiation after the surgery. The use of
tamoxifen is not recommended in this condition (Maughan et al. 2010). Breast cancer that has
progressed to either stage I or stage II, however, requires much more involved treatment plans. In
stage I and II, surgical treatment is almost always necessary. Radical mastectomy has been the
standard surgical treatment at these stages. However, breast-conserving surgery coupled with
radiation therapy has increased in frequency. Given the potential for metastasis at these stages, a
lymph node biopsy is usually performed to assess the spread of the cancer (Maughan et al. 2010).
Furthermore, chemotherapy, endocrine therapy, and tissue-targeted therapy are all used at these
stages of breast cancer. Chemotherapy will almost always be used when the cancer is either
node-positive or when there is a tumor larger than 1 centimeter. Chemotherapy is especially
necessary to treat those types of cancer that are hormone receptor-negative in nature. For those
types of cancer that are hormone receptor-positive, on the other hand, endocrine therapy can be
particularly helpful. Given that estrogen promotes the growth of these tumors, the treatments in
this category, such as tamoxifen, will either block estrogen production or serve as an estrogen
antagonist. Aromatase inhibitors also fall into this category as they prevent the formation of
estrogen from androgens (Maughan et al. 2010). Lastly, tissue-targeted therapy involves the use
of a monoclonal antibody that will bind the ERBB2 receptor that is overexpressed in some
cancer phenotypes (Maughan et al. 2010). For stage III breast cancer diagnoses, which are
characterized by tumors larger than 5 centimeters and migration to lymph nodes, induction
therapy is necessary. Induction therapy involves the use of chemotherapy to downsize the tumor
prior to operation on the tumor. Induction therapy can also be paired with the other treatment
options mentioned above (Maughan et al. 2010). Stage IV, or metastatic, breast cancer is very
lethal, with a five-year survival rate of only 23.3 percent (Maughan et al. 2010). Treatment of
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this stage of cancer is similar to stage I and II cancers: endocrine therapy is used to target
hormone receptor-positive cancers, tissue-targeted therapy is used for tumors overexpressing
ERBB2, and chemotherapy can be used in many situations. During this stage, which is very
lethal, the comfort of the patient must be considered when developing a treatment plan
(Maughan et al. 2010). Even with all of the current treatments that exist for breast cancer, there is
still a need to seek out new treatments. Effective treatments are those that have high target-tissue
specificity; in other words, the goal is to be able to target the cancer cells without harming the
healthy cells. Many genes have been associated with the development of cancer, and the use of
the CRISPR/Cas9 gene-editing tool may provide a specific method to target cancer cells.

CRISPR/Cas9 as a Gene-Editing Tool
The use of the CRISPR/Cas9 mechanism as a gene-editing tool is a relatively recent
development. The process of discovering this gene-editing tool began in 1987, when researchers
noticed repetitive sequences at the end of a bacterial gene. A decade later, biologists noticed that
these repetitive sequences were actually palindromic in nature and separated by regions of
“spacer DNA.” Even after the elucidation of these clustered regularly interspaced short
palindromic repeats (CRISPR), the function of these sequences was not yet determined.
However, in 2005, researchers in the field of bioinformatics discovered that the spacer DNA in
between the palindromic repeats matched viral DNA sequences. This led to the conjecture that
CRISPR serves as a form of adaptive immunity for bacteria against viruses (Pennisi 2013).
Given that bacteria and viruses have coevolved over the years, bacteria have been able to
develop a variety of defenses against viruses, such as bacteriophages. Many of the defenses that
bacteria have against viruses are innate, but adaptive immunity is also present within bacteria.
Danisco, a food science company, was able to demonstrate this adaptive immunity (Klug et al.
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2015). Danisco exposed Streptococcus thermophilus, a strain of bacteria that is commonly used
in the production of both cheese and yogurt, to bacteriophages; exposure of the bacteria to the
bacteriophages strengthened the defenses of the bacteria, essentially vaccinating this strain of
bacteria against the viruses (Pennisi 2013). The CRISPR/Cas system was determined to be
responsible for this adaptive immunity. The CRISPR/Cas system of adaptive immunity operates
in three basic steps: acquisition, crRNA biogenesis, and interference (Figure 3). The first step,
acquisition, begins when the foreign DNA of the virus is fragmented and inserted into a CRISPR
locus. This foreign DNA becomes the “spacer DNA” that is characteristic of these regions. Next,
during crRNA biogenesis, the CRISPR locus is transcribed to form crRNA. It is important to
mention that various CRISPR-associated (Cas) proteins are needed to process the crRNA that is
produced. During the interference stage, which is the last step, the mature crRNAs associate with
Cas proteins and bind to the complementary foreign DNA from which the crRNA was derived.
Then, the Cas proteins form a double-stranded break within the foreign DNA. It would seem that
these CRISPR/Cas complexes would also bind to and inactivate the original CRISPR locus due
to complementarity. However, these CRISPR/Cas complexes do not bind to the original CRISPR
locus that is present in the bacterial genome, and this is likely due to the CRISPR repeat
sequences that identify the sequence as “self” (Klug et al. 2015). The aforementioned mechanism
of the CRISPR/Cas system applies to its use within bacteria to provide adaptive immunity.
However, this system can be modified to be used in gene-editing. For example, Editas Medicine
sought to use the CRISPR/Cas technology to treat loss-of-function and gain-of-function
mutations. The mechanism that would be used to treat both of these mutations would involve
pairing single guide RNAs (sgRNAs) to the Cas9 endonuclease that produces double-stranded
breaks in the target DNA; the sgRNA, through complementary base-pairing, guides the Cas9
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Figure 3: The three basic steps of CRISPR/Cas adaptive immunity in bacteria (Klug et al. 2015).
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nuclease to the target sequence. In addition, a sequence must be included that is used as a
template during the repair of the double-stranded break. It is this repair of the double-stranded
break that impacts the mutation. In recessive disorders, the template sequence that is used for
repair is the dominant copy of the gene. In dominant disorders, the template sequence that is used
for repair is the recessive gene (Klug et al. 2015). In addition to treating recessive and dominant
disorders, CRISPR/Cas9 can also silence the expression of any gene through the same
mechanism. The sgRNA, Cas9 protein, and template sequence are usually encoded on a plasmid
that is inserted into target cells with a virus. In order to demonstrate the specificity of the
CRISPR/Cas9 system, researchers Jennifer Doudna and Emmanuelle Charpentier demonstrated
that varying single guide RNAs (sgRNAs) paired with the Cas9 nuclease can form doublestranded breaks in specific sequences of DNA (Pennisi 2013). In addition to having specificity,
CRISPR/Cas9 is also more affordable and easier to use than the other forms of gene-editing,
such as zinc-finger nucleases and transcription activator-like effector nucleases (TALENs). For
example, when using CRISPR/Cas9 in order to target a new site in the genome, only a new
sgRNA has to be synthesized; for zinc finger nucleases and TALENs, on the other hand, entirely
new proteins have to be synthesized for each newly targeted site within the genome (Xiao-Jie et
al. 2015). In addition, Addgene, a biotechnology company, is able to produce CRISPR constructs
for any variety of target sequences at an affordable price (Pennisi 2013). Given the capacity of
CRISPR/Cas9 to alter the expression of any number of genes, this gene-editing tool can be used
to alter those genes that have been explicitly implicated in causing breast cancer. One such gene
commonly examined in the development of breast cancer is angiomotin (Amot).
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The Angiomotin Target Sequence
Angiogenesis is the formation of new blood vessels from pre-existing vessels; this
process occurs during times of growth, such as embryological development. Angiogenesis also
plays a significant role in the development of cancer because growing tumors need both nutrients
and oxygen from the blood supply. The angiostatin protein is an inhibitor of angiogenesis, and
Amot serves as an inhibitor of angiostatin. Therefore, the angiomotin protein activates
angiogenesis in tumors (Jiang et al. 2006). There are two isoforms of Amot: Amot80 and
Amot130. The two isoforms perform seemingly opposite functions. For example, in a study of
retinal angiogenesis in postnatal mice, Amot80 was shown to be clearly expressed during those
postnatal days where retinal angiogenesis was expected. After retinal angiogenesis was
complete, expression of Amot130 predominated. This demonstrates that the Amot80 isoform is
associated with a migratory phenotype for cells that were forming new vessels, while the
Amot130 isoform was involved with the maturation and stabilization of the cells of the blood
vessels (Ernkvist et al. 2008).
In addition to angiogenesis, both angiomotin isoforms have been found to be involved in
the signal cascades responsible for the regulation of organ size. The Hippo pathway is commonly
considered to be responsible for controlling cell growth, and it is considered to be a tumorsuppressing pathway. Originally, it was thought that the Hippo pathway proceeds as follows:
MST1/2 protein kinases phosphorylate and activate LATS1/2 kinases, which then directly
phosphorylate and inactivate the pro-growth transcription factors of YAP and TAZ. However,
one study determined that LATS1/2 kinases likely phosphorylate Amot130, which increases the
stabilization of this isoform. Then, Amot130 and AIP4 likely form a complex that binds and
inhibits YAP. This conclusion was drawn due to the design of the study. For example, wild-type
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Amot130 is normally phosphorylated at a serine residue, which enables the protein to eventually
inhibit YAP. Growth of cells expressing the wild-type Amot130 was compared to those cells
expressing a mutant form of Amot130 that is not able to be phosphorylated at this particular
residue. The colonies of cells expressing wild-type Amot130, which was able to inhibit YAP,
were consequently much smaller than the colonies expressing a mutant form of Amot130, which
was not able to inhibit YAP. This demonstrates that functional Amot130 is necessary to prevent
pro-growth conditions in cells (Adler, Johnson, et al. 2013). The aforementioned association
between Amot130 and AIP4 was elucidated in a separate study that determined that significant
reduction in cell-growth was only seen in those cells that expressed both AIP4 and Amot130
(Adler, Heller, et al. 2013). Although the Amot130 isoform is involved with growth arrest, the
Amot80 isoform is involved in cellular proliferation. In particular, Amot80 promotes the
proliferation of mammary epithelial cells. Given that breast cancers originate from the
proliferation of the epithelial cells of either the ducts or lobules of the breast tissue, it is evident
that the gene coding for the Amot80 isoform could be a potential target for treatment. In mature
tissues that have an intact apical domain, growth arrest is important. It has been shown that
Amot80 can disrupt apical intercellular junctions; this is consistent with the aforementioned
finding that Amot80 is associated with the migratory phenotype in angiogenesis. One study
found that the mechanism by which Amot80 promotes the proliferation of mammary epithelia is
through the increased phosphorylation of extracellular signal-regulated kinases (ERK1/2). It is
thought that Amot80 promotes the activation of Raf by Ras; then, activated Raf eventually
activates ERK1/2 (Ranahan et al. 2011). In this same study, mammary cells were grown on
Matrigel, which simulates the extracellular matrix. Normally, non-transformed MCF10A cells
grown on the Matrigel will form hollow, fluid-filled ducts that resemble mammary ducts. The
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colonies of MCF10A cells that were expressing Amot80 at higher levels were larger than the
control colonies, and they lacked a hollow lumen (Ranahan et al. 2011). The increased
proliferation of MCF10A cells expressing Amot80 is a significant finding, especially considering
that MCF10A cells are non-tumorigenic in nature. This study alone warrants further
investigation into the role of Amot80 in breast cancer.
It has been demonstrated in many studies that the Amot80 isoform of the angiomotin
(Amot) gene is strongly associated with angiogenesis and the proliferation of mammary
epithelia. Furthermore, it has been discussed that the CRISPR/Cas9 gene-editing tool is both
specific and efficient. Therefore, it is reasonable that CRISPR/Cas9 could be used to reduce the
expression of Amot in tumorigenic cell lines. The AMOT CRISPRa sgRNA lentivector (set of
three targets) constructs will be used to attempt to reduce Amot expression in tumorigenic MDAMB-468 mammary epithelial cells. It is hypothesized that these constructs will significantly
reduce angiomotin expression, as confirmed by quantitative PCR of the cDNA generated from
the mRNA of the treated cells.
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Materials and Methods
Mammalian Tissue Culture
1. One vial (approximately 1 mL) of MDA-MB-468 human mammary epithelial cells was
taken out of the -80 ℃ freezer.
2. As the cells were thawing, 10 mL of properly prepared Leibovitz-15 (L-15) media (10%
FBS and 1% antibiotic/antimycotic) was transferred to a 10-cm tissue culture plate.
3. Before the cells thawed entirely, the cells were poured from the vial into the 10-cm tissue
culture plate in a sterile tissue culture hood.
4. After the cells were added to the media, the plate was gently moved in a forwardbackward, side-to-side, and circular motion to distribute the cells across the plate.
5. The MDA-MB-468 cells were transferred to a 37 ℃ and 0% CO2 incubator.
6. The next day, the cells were examined to determine their health, and the old media was
aspirated off of the plate without disturbing the cells on the plate.
7. 10 mL of fresh Leibovitz-15 media was gently added to the plate, and the cells were
returned to the incubator.
8. Following at least a day after media transfer, the cells were split in a 1:1 ratio onto
another 10-cm plate. (Note: the ratio at which the cells were split varies according to
confluency of the cells on the plate.)
9. To begin the splitting process, the tissue culture hood was prepared and sterilized, the
aspirator line was flushed, and all necessary materials were sterilized before being placed
in the hood.
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10. After preparations were made for the process, the media was carefully aspirated off of the
cells.
11. 1 mL of PBS was added to the plate without disrupting the cells, and the PBS was also
aspirated off of the plate.
12. Then, 2 mL (volumes can vary depending on the size of the plate) of 1X trypsin was
added to the plate, and the plate was returned to the incubator.
13. The plate was gently agitated every 2 to 5 minutes until all of the cells were in
suspension.
14. An equal volume of total media was added to the plate at a 45º angle in order to
neutralize the trypsin. (Note: the plate was kept at this angle in order to keep the cells
from adhering to the base of the plate again.)
15. The total volume (4 mL in this case) was transferred to a 15-mL falcon.
16. The falcon was spun at 1500 xg for 1.5 minutes.
17. A new 10-cm plate (or any other plate size) was labeled with the cell type, the passage
number, the researcher’s initials, and the date.
18. 10 mL of fresh Leibovitz-15 media was added to the new plate.
19. The supernatant in the 15-mL falcon was aspirated off without disrupting the pellet of
cells that was in the bottom of the falcon.
20. Using a P1000 pipet, 1 mL of Leibovitz-15 media was used to resuspend the pellet (the
pellet was broken up by pipetting up and down at least 40 times).
21. The resuspended cells were pipetted onto the new plate.
22. This plate was moved in a forward-backward, side-to-side, and a circular motion to
evenly distribute the cells on the plate.
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23. The plate was transferred to a 37 ℃ and 0% CO2 incubator.

Pouring LB/Ampicillin Plates
1. A 500-mL glass bottle was selected in order to prepare 250 mL of the LB/ampicillin agar
solution.
2. 5 Lennox tablets, containing LB broth with agar, were added to 250 mL of non-sterilized
Millipore water (this was consistent with the order to add 1 tablet per 48.3 mL of water).
3. Using an automatic magnetic stirrer, the tablets were dissolved in the water.
4. Then, the lid for the container was placed on the container loosely, and foil was placed
over the lid. Lastly, a piece of autoclave tape was placed on the foil.
5. The container was placed in a plastic tub containing just enough water to cover the
bottom of the tub.
6. A 15-minute wet cycle was selected.
7. A 55 ℃ water bath was prepared.
8. After the wet cycle was complete, the container of autoclaved LB/agar broth was
transferred to the water bath.
9. The temperature of the broth was periodically checked with a sterilized thermometer,
until the temperature of the broth was at about 55 ℃.
10. While waiting for the LB/agar solution to cool, twenty 10-cm plates were prepared in a
sterile hood; each plate was labelled as “LB/amp” with the date.
11. When the temperature cooled to the aforementioned temperature, 250 µL of the 1000X
ampicillin solution was transferred to the LB/agarose solution.
12. The LB/agar solution was swirled in order to mix the ampicillin antibiotic in the LB/agar
solution.
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13. Enough (approximately 10 mL) of the LB/agar/ampicillin solution was added to each
plate in order to cover the bottom of the plate.
14. After all of the plates were poured, the plates were cooled until solid. (Note: the lids were
propped open to prevent condensation build-up.)
15. The plates were transferred back into the original bag, the bag was labelled appropriately,
and the bag was placed in the refrigerator for storage.

DH5α Transformation
1. One tube of DH5α cells was removed from the -80 ℃ freezer and thawed on ice.
2. The vial containing Scrambled sgRNA CRISPR/Cas9 All-in-one Lentivector was
removed from the -4 ℃ freezer and placed in ice to thaw; the three vials containing the
three constructs of AMOT CRISPRa sgRNA lentivector (set of three targets) were also
removed from the same freezer and placed in ice to thaw.
3. Four 1.5-mL microcentrifuge tubes were assigned one of the following labels: CNTRL
(for Scrambled CRISPR), Red (for Amot 98), Yellow (for Amot 174), and Green (for
Amot 257).
4. After the DH5α cells thawed, a 50-µL volume of cells was transferred into each of the
four microcentrifuge tubes.
5. The unused cells were placed back into the -80 ℃ freezer.
6. 1 µL of each DNA construct was added to the properly labelled tube, and the DNA
constructs and cells were gently swirled with the pipet tip.
7. The tubes were incubated on ice for 30 minutes.
8. Each tube of cells was heat shocked for 20 seconds without shaking on a heat block set to
42 ℃.
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9. The tubes were incubated on ice again for 2 minutes.
10. 950 µL of pre-warmed SOC media was transferred to each tube.
11. The tubes were then incubated in a shaking incubator at 37 ℃ for 1 hour at 225 rpm.
12. Three LB/ampicillin plates were selected per construct and were labelled with the
construct and the amount of volume pipetted onto the plate (either 50 µL, 100 µL, or 300
µL).
13. For each construct, the volumes specified by each plate were pipetted onto the plate and
were spread with a sterile inoculation loop in a manner that dilutes the colonies across the
plate.
14. The plates were flipped upside down to prevent the accumulation of condensation and
were placed in a 37 ℃ incubator overnight.
15. The remaining transformation reactions were stored in the refrigerator indefinitely.
16. The next day, 50 mL of LB/ampicillin broth was prepared with the same concentration of
ampicillin (1 µL of ampicillin/1 mL of LB broth) as the plates.
17. Four 3-mL tubes were filled with 3 mL of the LB/ampicillin broth and were labelled for
each construct.
18. Colonies were transferred from the plates of each construct into the corresponding tubes
of LB/ampicillin broth.
19. The tubes containing the inoculated broth were placed into the shaking incubator that was
set to 37 ℃ and 225 rpm for 18 hours.
20. The tubes were inspected for growth.
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Bacterial Plasmid DNA “Mini-Prep”
1. The tubes of broth were inspected for growth, and one tube with significant bacterial
growth was selected per construct.
2. 1.5 mL of the broth was transferred to the appropriately labeled 2-mL microcentrifuge
tube. This was repeated for each construct.
3. The tubes were centrifuged at 15,000 xg for 3 minutes.
4. The supernatant was removed, leaving a pellet at the bottom of the tube.
5. Steps 2-4 were repeated to use the remaining volume of the selected liquid cultures.
6. The pellets of bacteria were then stored in the -4 ℃ freezer.
7. 50 mL of solution 1 (TE Resuspension Buffer) was prepared by adding 2.5 mL of 0.5 M
Tris at a pH of 8.0, 500 µL of 1 M EDTA at a pH of 8.0, 0.45 g of glucose, 100 µL of a
50 mg/mL stock solution of Rnase, and a volume of distilled water that makes the total
volume 50 mL. Solution 1 was stored in the 4 ℃ refrigerator.
8. 50 mL of solution 2 (NaOH/SDS Lysis Buffer) was prepared by adding 0.5 g of SDS
powder to make the concentration 1% and by adding 10 mL of 1 M NaOH to make the
final concentration of NaOH 0.2 M. Distilled water was added to make the total volume
50 mL.
9. 50 mL of solution 3 (KOAc Neutralization Buffer) was prepared by adding 50 mL of 5 M
potassium acetate to a 50-mL falcon; additionally, glacial acetic acid was added until the
pH of the solution was 4.8. This solution was stored at room temperature.
10. The microcentrifuge tubes containing the pellets of bacterial cells transformed by each
construct were removed from the -4 ℃ freezer.
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11. 200 µL of solution 1 was added to the pellet of each tube, and the pellet was resuspended
by pipetting up and down.
12. 200 µL of solution 2 was added to each tube, and the tubes were inverted several times to
mix. The samples were assessed to ensure that each sample was clear at this point.
13. 200 µL of solution 3 was added to each tube, and the tubes were inverted to mix. The
samples were assessed to ensure that each sample had a white precipitate.
14. The tubes were centrifuged at 15,000 xg for 5 minutes in the mini centrifuge.
15. The supernatant was removed from each tube and transferred to a new tube that was
properly labeled. The tubes containing white precipitate were discarded.
16. Each tube was inspected for any particulates; if any particulates were present, steps 14
and 15 were repeated.
17. After ensuring there were no particulates in the new tubes, 1 mL of 100% ethanol was
added to each tube.
18. The tubes were centrifuged at 15,000 xg for 5 minutes in the mini centrifuge.
19. The ethanol was removed, making sure not to disrupt the pellet in the process.
20. 1 mL of 70% ethanol was added to each tube; the pellet of each tube was dislodged in
this step.
21. The tubes were centrifuged at 15,000 xg for 2 minutes in the mini centrifuge.
22. All of the ethanol was removed by pipetting progressively smaller volumes of ethanol off
of the pellet of each tube.
23. Once all of the ethanol was removed, the pellet of each tube was allowed to air dry for 510 minutes.
24. Each pellet was resuspended with 50 µL of TE solution.
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25. The optical density and concentration of each DNA sample were determined through the
use of the NanoDrop Lite Spectrophotometer.
26. The prepared DNA was stored in the 4 ℃ refrigerator until needed for transfections.

Bacterial Glycerol Stock Preparation
1. Eight cryovials were selected, and two cryovials were designated for each construct; for
example, two cryovials were labeled with Scrambled CRISPR, Amot 98, Amot 174, or
Amot 257.
2. 500 µL of 50% glycerol was added to each cryovial.
3. 500 µL of the liquid culture transformed with the Scrambled CRISPR plasmid was added
to the corresponding cryovials. The liquid culture was resuspended by pipetting up and
down prior to adding liquid culture to the cryovial.
4. Step 3 was repeated for each CRISPR construct (i.e., Amot 98, Amot 174, and Amot
257).
5. Once all of the glycerol stocks were prepared, the eight cryovials were put into the -80 ℃
freezer for long-term storage of the bacteria transformed with the desired DNA
constructs.

6-Well Plate Cell Assay
1. After the DNA was prepared, the MDA-MB-468 cells that were in culture were inspected
for adequate growth.
2. Once the MDA-MB-468 cells were determined to be at a confluency (approximately 70%
confluent) that was sufficient for a 6-well plate cell assay, preliminary calculations were
performed to prepare the two 6-well plates that were needed for the experiment.
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3. It was determined that 600,000 cells should be added to each well.
4. The calculation for total cells needed was performed by multiplying the 600,000
cells/well by 13 wells (to provide extra cells to prevent error); this yielded a total of
7,800,000 cells.
5. The total volume of media that will be added to the two 6-well plates was determined to
be 26 mL (2 mL of media per well x 13 wells).
6. After these preliminary calculations, two 10-cm plates of MDA-MB-468 cells were
selected to be used in the 6-well plate assay.
7. To begin the process, the cells were split using normal tissue culture techniques.
8. The old media was aspirated off of each plate.
9. 1 mL of 1X PBS was added to each plate, and the PBS solution was then aspirated off of
each plate.
10. Then, 2 mL of 1X trypsin was added to each plate, and the plates were placed into the
37 ℃ incubator for 8 to 12 minutes. The plates were gently agitated and examined every
2-5 minutes to determine if the cells were detached from the plate.
11. After all cells were detached from the plate, an equal volume of L-15 media (2 mL) was
added to each plate.
12. The cells from both plates were transferred to a 15-mL falcon and were spun at 1500 xg
for 1.5 minutes.
13. The media was carefully aspirated off of the pellet, and the pellet was resuspended with 1
mL of L-15 media.
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14. Immediately after resuspension, 10 µL of the suspended cell solution was added to a 10µL drop of trypan blue that was placed on a piece of parafilm. The cells were mixed with
the trypan blue by pipetting up and down.
15. After mixing the cells with the trypan blue, 10 µL of the stained cells was added to the
opening of a cell counter slide at a 45º angle. The cell counter slide was inserted into the
Bio-Rad Automated Cell Counter, and the cell count was too high for the Automated Cell
Counter to determine the exact cell count.
16. The resuspended cells were resuspended with an additional 1 mL of L-15 media, and the
same process was repeated as described in steps 14 and 15.
17. The live cell count was determined to be 6.78 x 106 cells/mL.
18. After determining the cell count, it was determined that 1,150 µL of the resuspended
solution of cells would be needed to provide the 7,800,000 cells for the two 6-well plate
assays.
19. A 50-mL falcon was acquired, and 26 mL of L-15 media was added to the falcon.
20. Then, the solution of cells was thoroughly resuspended, and 1 mL (or 1000 µL) of the
resuspended solution was added to the falcon containing the L-15 media. The solution of
cells was resuspended again, and the remaining 150 µL of the resuspended cell solution
was added to the falcon containing the L-15 media.
21. The two 6-well plates were acquired and labeled as follows: the first plate was labeled
with “CNTRL” for row A and “Amot 98” for row B, and the second plate was labeled
with “Amot 174” for row A and “Amot 257” for row B. In addition, the plates were
labeled with the experimenter’s initials, the passage number of the cells, and the date.
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22. The suspension of cells was inverted to mix the cells, and a pipet aid with a 10-mL pipet
tip was used to collect 6 mL of the resuspended cell solution. Then, 2 mL of the
resuspended cell solution was added to each well of the first row.
23. Step 22 was repeated for the other 3 rows.
24. After 2 mL of the resuspended cell solution was added to each well, the two 6-well plates
were added to the 37℃ and 0% CO2 incubator.
25. The remaining volumes of cell suspension in the 15-mL falcon and the 50-mL falcon
were combined and added to two 10-cm tissue culture plates containing fresh L-15
media. These plates were also placed in the 37℃ and 0% CO2 incubator.

Transient Transfection Protocol
1. After 24 hours, the 6-well plates were inspected to determine if there were enough cells
present for transfection.
2. The L-15 media was aspirated off of the cells in each well, and 1 mL of Opti-MEM was
transferred to each well.
3. The 6-well plates were placed in the 37 ℃ and 0% CO2 incubator while the remainder of
the transfection protocol was taking place.
4. It was previously determined that each construct would be tested at three different
concentrations: 1 µg, 2 µg, and 4 µg.
5. Given the varying concentrations of each DNA construct, calculations were performed to
determine what volume of each DNA construct would have to be added to yield the
desired concentration of DNA.
6. After these calculations were performed, 15 1.5-mL microcentrifuge tubes were acquired;
twelve tubes were set aside for the preparation of the DNA, and three tubes were set aside
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for the preparation of the transfectin reagent. Each set of three 1.5-mL microcentrifuge
tubes were labeled with the appropriate construct and the concentration (either 1 µg, 2
µg, or 4 µg). The remaining three tubes were labeled with “transfectin” and one of three
volumes of the reagent: 2 µL, 4 µL, or 8 µL.
7. The concentrations of each DNA construct were used to determine how much of the
solution containing the DNA needed to be added to provide 1 µg, 2 µg, or 4 µg of the
DNA.
8. Prior to adding any DNA to any tubes, 250 µL of Opti-MEM was added to each of the
twelve tubes.
9. For the Scrambled CRISPR construct, 2.4 µL of the DNA was added to the 1-µg tube, 4.9
µL was added to the 2-µg tube, and 9.7 µL was added to the 4-µg tube.
10. For the Amot 98 construct, 1.95 µL of the DNA was added to the 1-µg tube, 3.9 µL was
added to the 2-µg tube, and 7.8 µL was added to the 4-µg tube.
11. For the Amot 174 construct, 1.4 µL of the DNA was added to the 1-µg tube, 2.8 µL was
added to the 2-µg tube, and 5.6 µL was added to the 4-µg tube.
12. For the Amot 257 construct, 3.7 µL of the DNA was added to the 1-µg tube, 7.3 µL was
added to the 2-µg tube, and 14.6 µL was added to the 4-µg tube.
13. Given that 2 µL of transfectin needs to be added to each tube of 1 µg of DNA, one large
aliquot was prepared. This aliquot was formed by adding 10 µL of transfectin to 1,250
µL of Opti-MEM. (Note: A 5X aliquot was made to ensure that there was extra solution
available.)
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14. Given that 4 µL of transfectin needs to be added to each tube of 2 µg of DNA, one large
aliquot was prepared. This aliquot was formed by adding 20 µL of transfectin to 1,250
µL of Opti-MEM.
15. Given that 8 µL of transfectin needs to be added to each tube of 4 µg of DNA, one large
aliquot was prepared. This aliquot was formed by adding 40 µL of transfectin to 1,250
µL of Opti-MEM.
16. After the aliquots of transfectin were prepared, 250 µL of the 2-µL transfectin aliquot
was added to the 1-µg tube of Scrambled CRISPR DNA. Then, 250 µL of the 4-µL
transfectin aliquot was added to the 2-µg tube of Scrambled CRISPR DNA. Finally, 250
µL of the 8-µL transfectin aliquot was added to the 4-µg tube of Scrambled CRISPR
DNA.
17. The same volumes of each transfectin aliquot were added to each concentration of DNA
for the other three constructs.
18. The tubes containing both the DNA and the transfectin were allowed to incubate at room
temperature for 20 minutes.
19. After this incubation period, the entire volume of the solution containing 1 µg of
Scrambled CRISPR DNA and 2 µL of transfectin was added to the well that corresponds
to 1 µg of the Scrambled CRISPR DNA. This solution was added dropwise to the
solution while the plate was tilted; after adding a few drops, the plate would be moved
forward and backward to distribute the DNA equally.
20. Step 19 was repeated for each construct at each concentration. (Note: Special care was
taken to prevent cross-contamination of DNA in different wells.)
21. The 6-well plates were then placed in the 37 ℃ and 0% CO2 incubator.
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22. After six hours of incubation, 1 mL of Opti-MEM was added to each well.
23. The 6-well plates were inspected at 24 hours, 48 hours, and 72 hours of incubation.
24. At 48 hours, the 4-µg wells for each construct were harvested.
25. To harvest the cells, the media was aspirated off of each well, and 500 µL of Trizol was
added to the cell culture in each well. (Note: Special precautions were taken when Trizol
was in use.)
26. The viscous solution that resulted from the addition of the Trizol solution was transferred
to a 1.5-mL tube that was labeled with the proper DNA construct (i.e., Scrambled, Amot
98, Amot 174, or Amot 257) along with the concentration of the DNA (1 µg, 2 µg, or 4
µg). These tubes could be stored in a -20 ℃ freezer until needed for an RNA extraction.
27. At 72 hours, the 1-µg and 2-µg conditions were both harvested by repeating steps 25 and
26.
28. All of the tubes were stored in the -20 ℃ freezer until needed for the RNA extraction.

RNA Extraction
1. Prior to beginning the RNA extraction process, the tissue culture hood was prepared by
spraying RNAse-away on all surfaces that would be touched throughout the process.
2. A bucket of ice was collected and wiped down with RNAse-away before being inserted
into the culture hood.
3. The tubes containing the harvested cells were removed from the freezer, wiped down
with RNAse away, and allowed to thaw.
4. While the tubes were thawing, the refrigerated centrifuge was turned on and set to 13,000
xg and 4 ℃.
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5. After the tubes were able to incubate at room temperature for about 5 minutes, 0.2 mL of
chloroform was added to each tube containing Trizol.
6. After adding chloroform to each tube, the tubes were vortexed and incubated at room
temperature for 5 minutes.
7. After this room temperature incubation, the tubes were centrifuged at 13,000 xg for 10
minutes at 4 ℃. After this, the tubes were immediately put on ice. (Note: the tubes were
kept on ice at all times unless a specific room temperature incubation was required.)
8. The top layer (aqueous layer) of each tube was transferred to a new tube that was labeled
appropriately. (Note: if any contamination occurred, the aqueous layer was pipetted back
into the tube, and step 9 was followed until the transfer was successful.)
9. The tubes were centrifuged again at 13,000 xg for 3 minutes at 4 ℃ if any contamination
occurred (such as the disruption of any of the other layers).
10. Once the aqueous layer of each tube was successfully transferred to a new tube that was
appropriately labeled, 500 µL of isopropanol was added to each tube.
11. After adding isopropanol to each tube, 0.5 µL of glycoblue was added to each tube.
(Note: the glycoblue was pipetted directly into the liquid layer.)
12. After the addition of isopropanol and glycoblue, the tubes were vortexed, incubated at
room temperature for 5 minutes, and centrifuged at 13,000 xg for 10 minutes at 4 ℃.
13. The isopropanol was removed from each tube without disrupting the blue pellet at the
bottom of each tube.
14. After removing as much isopropanol as possible from each tube, 500 µL of 75% ethanol
was added to each tube. (Note: the pellet was purposefully dislodged at this step.)
15. The tubes were spun at 13,000 xg for 5 minutes at 4 ℃.
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16. The ethanol was carefully removed from each pellet through the successive use of
adjustable pipets with smaller volume capacities (i.e., P1000 to P200 to P10 to P2).
17. With just a miniscule amount of ethanol left in the bottom of the tube, the tubes were
spun in a table-top centrifuge to spin down any remaining ethanol. A P2 pipet was then
used to remove the last bit of ethanol.
18. The tubes were left open for 5 minutes to allow the pellet to dry. (Note: care was taken to
prevent any ice from getting into the open tubes.)
19. After all of the ethanol was removed from each tube and each pellet was allowed to dry
for about 5 minutes, the pellet was resuspended with 20-50 µL of nuclease free water.
(Note: the pellet was mixed by pipetting up and down at least 100 times.)
20. The optical density and concentration of each sample was determined through the use of
the NanoDrop Lite Spectrophotometer. The optical density and concentration of each
sample was written on the tube.
21. The tubes containing the RNA were placed in the -20 ℃ freezer until cDNA needed to be
generated.

cDNA Synthesis
1. The tissue culture hood was prepared by wiping down all surfaces with RNAse-away.
2. The RNA samples were removed from the -20 ℃ freezer, wiped off with RNAse-away,
and put on ice to thaw. The 5x iScript advance reaction mix and iScript advanced reverse
transcriptase was acquired and put on ice to thaw. Finally, an aliquot of nuclease-free
water was acquired and put on ice.
3. Calculations were performed to determine the exact amount of RNA template that needed
to be added to a PCR tube to yield 1 µg of total RNA.
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4. Instead of using individual PCR tubes for the cDNA synthesis, the top row of a 96-well
plate was used.
5. The reagents for cDNA synthesis were added in the following order: nuclease-free water,
RNA template, reaction mix, and then reverse transcriptase.
6. The 1 µg, 2 µg, and 4 µg samples of Scrambled CRISPR (CNTRL) were assigned to
wells A1, A2, and A3, respectively. The three samples of Amot 98 were assigned in the
same order to wells A4, A5, and A6; the three samples of Amot 174 were assigned to
wells A7, A8, and A9; and the three samples of Amot 257 were assigned to wells A10,
A11, and A12.
7. In A1, 12.5 µL of nuclease-free water, 2.5 µL of CNTRL 1 µg RNA template, 4 µL of
reaction mix, and 1 µL of reverse transcriptase were added to the bottom of the well.
8. In A2, 1.8 µL of nuclease-free water, 13.2 µL of CNTRL 2 µg RNA template, 4 µL of
reaction mix, and 1 µL of reverse transcriptase were added to the bottom of the well.
9. In A3, 2.4 µL of nuclease-free water, 12.6 µL of CNTRL 4 µg RNA template, 4 µL of
reaction mix, and 1 µL of reverse transcriptase were added to the bottom of the well.
10. In A4, 13.3 µL of nuclease-free water, 1.7 µL of Amot 98 1 µg RNA template, 4 µL of
reaction mix, and 1 µL of reverse transcriptase were added to the bottom of the well.
11. In A5, 1.7 µL of nuclease-free water, 13.3 µL of Amot 98 2 µg RNA template, 4 µL of
reaction mix, and 1 µL of reverse transcriptase were added to the bottom of the well.
12. In A6, 9.6 µL of nuclease-free water, 5.4 µL of Amot 98 4 µg RNA template, 4 µL of
reaction mix, and 1 µL of reverse transcriptase were added to the bottom of the well.
13. In A7, 12.8 µL of nuclease-free water, 2.2 µL of Amot 174 1 µg RNA template, 4 µL of
reaction mix, and 1 µL of reverse transcriptase were added to the bottom of the well.
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14. In A8, 0 µL of nuclease-free water, 21.8 µL of Amot 174 2 µg RNA template, 4 µL of
reaction mix, and 1 µL of reverse transcriptase were added to the bottom of the well.
15. In A9, 4.9 µL of nuclease-free water, 10.1 µL of Amot 174 4 µg RNA template, 4 µL of
reaction mix, and 1 µL of reverse transcriptase were added to the bottom of the well.
16. In A10, 13.1 µL of nuclease-free water, 1.9 µL of Amot 257 1 µg RNA template, 4 µL of
reaction mix, and 1 µL of reverse transcriptase were added to the bottom of the well.
17. In A11, 4.1 µL of nuclease-free water, 10.1 µL of Amot 257 2 µg RNA template, 4 µL of
reaction mix, and 1 µL of reverse transcriptase were added to the bottom of the well.
18. In A12, 9.6 µL of nuclease-free water, 5.4 µL of Amot 257 4 µg RNA template, 4 µL of
reaction mix, and 1 µL of reverse transcriptase were added to the bottom of the well.
19. The 96-well plate was sealed tightly with the plastic cover for the plate, and the 96-well
plate was put into the Bio-Rad CFX96 Real-Time System thermal cycler. The parameters
were programmed as follows: 30 minutes at 42 ℃ and 5 minutes at 85 ℃.
20. The cDNA was stored in the 4 ℃ refrigerator until needed for qPCR.

Quantitative PCR (qPCR)
1. It was decided that three 96-well plates would be set up: one for the 1-µg condition of
each construct, one for the 2-µg condition of each construct, and one for the 4-µg
condition of each construct.
2. In each plate, the general layout was the same. In rows A and E, the target was ß-actin; in
rows B and F, the target was GAPDH; in rows C and G, the target was Amot; and in rows
D and H, the target was PCNA.
3. The first quadrant of each plate (A1-A4, B1-B4, C1-C4, D1-D4) was designed to be for
the CNTRL samples.
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4. The second quadrant of each plate (E1-E4, F1-F4, G1-G4, H1-H4) was designed to be for
the Amot 98 samples.
5. The third quadrant of each plate (A6-A9, B6-B9, C6-C9, D6-D9) was designed to be for
the Amot 174 samples.
6. The fourth quadrant of each plate (E6-E9, F6-F9, G6-G9, H6-H9) was designed to be for
the Amot 257 samples.
7. The no-template controls for each plate were designated for wells G11, G12, H11, and
H12.
8. After designing the layout of each plate, the primer master mixes were prepared.
9. The forward and reverse primers for each target, SYBR green super mix, and doubledistilled water (ddH2O) were acquired and put on ice in the tissue culture hood.
10. Four 1.5-mL microcentrifuge tubes were acquired and labeled with one of the four
targets.
11. The ß-actin master mix was prepared by adding 52 µL of ddH2O, 28 µL of forward and
reverse ß-actin primers (at 3µM concentration), and 100 µL of the SYBR green super
mix to a 1.5-mL tube. The master mix was kept on ice after preparation. (Note: the
primer master mixes were prepared at 20X instead of 1X.)
12. The GAPDH master mix was prepared by adding 52 µL of ddH2O, 28 µL of forward and
reverse GAPDH primers (at 3µM concentration), and 100 µL of the SYBR green super
mix to a 1.5-mL tube. The master mix was kept on ice after preparation.
13. The Amot master mix was prepared by adding 52 µL of ddH2O, 28 µL of forward and
reverse Amot primers (at 3µM concentration), and 100 µL of the SYBR green super mix
to a 1.5-mL tube. The master mix was kept on ice after preparation.
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14. The PCNA master mix was prepared by adding 52 µL of ddH2O, 28 µL of forward and
reverse PCNA primers (at 3µM concentration), and 100 µL of the SYBR green super mix
to a 1.5-mL tube. The master mix was kept on ice after preparation.
15. The no-template controls were prepared as a 5X master mix. For example, 20 µL of
ddH2O, 5 µL of forward and reverse ß-actin primers (at 3 µM concentration), and 25 µL
of the SYBR green super mix were added to a 1.5-mL tube.
16. 10 µL of the no-template control master mix was added to wells G11, G12, H11, and
H12. This section of wells was kept covered by the plastic cover when adding the primer
master mix and the cDNA samples to the 96-well plate.
17. 9 µL of the ß-actin primer mix was added to wells A1-A9 (column 5 was excluded for
every row) and wells E1-E9.
18. 9 µL of the GAPDH primer mix was added to wells B1-B9 and wells F1-F9.
19. 9 µL of the Amot primer mix was added to wells C1-C9 and wells G1-G9.
20. 9 µL of the PCNA primer mix was added to wells D1-D9 and wells H1-H9.
21. After all of the primers were loaded, the primers, SYBR green super mix, and the ddH2O
were placed back into the -4 ℃ freezer, the -20 ℃ freezer, and the 4 ℃ refrigerator,
respectively.
22. The 96-well plate was removed from the 4 ℃ refrigerator and placed in the tissue culture
hood.
23. 1 µL of the CNTRL 1 µg sample was loaded directly into each well containing primer
mix in the first quadrant. (Note: the pipet tip was changed for each well.)
24. 1 µL of the Amot 98 1 µg sample was loaded directly into each well containing primer
mix in the second quadrant.
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25. 1 µL of the Amot 174 1 µg sample was loaded directly into each well containing primer
mix in the third quadrant.
26. 1 µL of the Amot 257 1 µg sample was loaded directly into each well containing primer
mix in the fourth quadrant.
27. The fully prepared 96-well plate was sealed tightly with the adhesive cover; after sealing,
the plate was vortexed and centrifuged.
28. The plate was inserted into the Bio-Rad CFX96 Real-Time System with well A1 in the
top left corner.
29. The program entitled “Universal iScript Advanced” was selected on the thermal cycler.
30. The specific parameters of this program were programmed as follows: 1 cycle of 95 ℃
for 30 seconds; 35-40 cycles of 95 ℃ for 10 seconds and 60 ℃ for 20 seconds; and a
melt-curve analysis that proceeded from 65 ℃ to 95 ℃ in 0.5 ℃ increments (image
capturing occurred every 0.5 ℃).
31. The raw data was collected from the CFX96 Real-Time System and analyzed with the
Bio-Rad CFX Maestro program.
32. Steps 9-31 were repeated for the 2-ug and 4-ug samples.
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Results
After performing the bacterial plasmid DNA “mini-prep,” the optical density and
concentration were determined for each construct (Table 1). The A260/280 reading is the
Table 1: Optical density and concentration for each CRISPR construct
Construct

A260/280

Concentration

Scrambled CRISPR

1.95

411.9 ng/µL

Amot 98

2.00

513.0 ng/µL

Amot 174

2.00

712.9 ng/µL

Amot 257

1.99

273.4 ng/µL

(CNTRL)

“optical density” of each construct. It was apparent that each construct had a A260/280 value
that was either exactly 2.00 or extremely close to that value. A value of 2.00 for the A260/280
reading is ideal for a pure DNA sample. This DNA was used to transfect the MDA-MB-468 cells
at varying concentrations. For the 4-µg condition, the cells were harvested after 48 hours of
transient transfection due to significant deterioration of the health of the cells; for the 1-µg and
the 2-µg conditions, however, the cells were able to be incubated for 72 hours before harvesting
the cells. After harvesting the cells at each condition, an RNA extraction was performed. After
performing the RNA extraction, the optical density and concentration were determined for each
sample (Table 2). Similar to a DNA sample, a value of 2.00 for the A260/280 is considered pure
for RNA samples. Each RNA sample had a value close to 2.00 for the A260/280 reading (Table
2). In addition, the concentration of each RNA sample was sufficient for a cDNA preparation.
After the generation of cDNA, quantitative polymerase chain reaction (qPCR) was performed to
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Table 2: Optical density and concentration for each RNA sample
Sample

A260/280

Concentration (ng/µL)

CNTRL 1 µg

1.91

404.3 ng/µL

Amot 98 1 µg

1.98

573.2 ng/µL

Amot 174 1 µg

1.98

451.6 ng/µL

Amot 257 1 µg

1.96

535.2 ng/µL

CNTRL 2 µg

1.95

75.7 ng/µL

Amot 98 2 µg

1.94

75.4 ng/µL

Amot 174 2 µg

1.92

45.9 ng/µL

Amot 257 2 µg

1.94

91.6 ng/µL

CNTRL 4 µg

1.88

79.4 ng/µL

Amot 98 4 µg

1.96

186.8 ng/µL

Amot 174 4 µg

1.96

98.7 ng/µL

Amot 257 4 µg

1.99

186.4 ng/µL
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analyze relative expression of the target genes of angiomotin (Amot) and proliferating cell
nuclear antigen (PCNA) in each sample.
Quantitative PCR was performed for each condition: the 1-µg condition, the 2-µg
condition, and the 4-µg condition. Within each condition, the impacts of the Amot 98, Amot 174,
and Amot 257 CRISPR constructs on the relative gene expression of the aforementioned targets
were compared to those of Scrambled CRISPR, the control sample. In the 1-µg condition, each
cDNA sample was targeted for expression of ß-actin, GAPDH, Amot, and PCNA, and the Cq
values were determined through the use of the Bio-Rad CFX96 Real-Time System (Table 3).
Each target was performed in quadruplicate, so the mean Cq values were important in the
eventual calculation of ∆∆Cq. For the Scrambled CRISPR (or CNTRL) sample, the mean Cq
value for ß-actin was 16.24; the mean Cq value for GAPDH was 15.86; the mean Cq value for
Amot was 20.05; and the mean Cq value for PCNA was 17.48. With the targets in the same order
for the Amot 98 samples, the mean Cq values were determined to be 16.36, 15.84, 19.75, and
17.07. For the Amot 174 samples, the mean Cq values were determined to be 16.30, 15.86,
20.35, and 17.73. Lastly, for the Amot 257 samples, the mean Cq values were determined to be
15.74, 15.52, 19.46, and 17.08. In the no-template control samples, the mean Cq value was
determined to be 38.09. In addition to simply determining the Cq values for each sample, melt
temperature analysis was performed (Table 3). For each sample targeting ß-actin, the melt
temperature was determined to be 89.5 ℃. For each sample targeting GAPDH, the melt
temperature was determined to 85 ℃. For each sample targeting Amot, the melt temperature was
determined to be 84 ℃. For each sample targeting PCNA, the melt temperature was determined
to be 86 ℃. Finally, for the no-template control samples, no melt temperature was determined.
The acquisition of the Cq values was important to determining relative normalized expression of
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Table 3: Cq values and melt temperatures across the 1-µg condition
Target
Actin
Actin
Actin
Actin
GAPDH
GAPDH
GAPDH
GAPDH
Amot
Amot
Amot
Amot
PCNA
PCNA
PCNA
PCNA
Actin
Actin
Actin
Actin
GAPDH
GAPDH
GAPDH
GAPDH
Amot
Amot
Amot
Amot
PCNA
PCNA
PCNA
PCNA
Actin
Actin
Actin
Actin
GAPDH
GAPDH
GAPDH
GAPDH
Amot
Amot
Amot
Amot
PCNA
PCNA
PCNA
PCNA

Content
Pos Ctrl
Pos Ctrl
Pos Ctrl
Pos Ctrl
Pos Ctrl
Pos Ctrl
Pos Ctrl
Pos Ctrl
Pos Ctrl
Pos Ctrl
Pos Ctrl
Pos Ctrl
Pos Ctrl
Pos Ctrl
Pos Ctrl
Pos Ctrl
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn

Sample
Cntrl 1 ug
Cntrl 1 ug
Cntrl 1 ug
Cntrl 1 ug
Cntrl 1 ug
Cntrl 1 ug
Cntrl 1 ug
Cntrl 1 ug
Cntrl 1 ug
Cntrl 1 ug
Cntrl 1 ug
Cntrl 1 ug
Cntrl 1 ug
Cntrl 1 ug
Cntrl 1 ug
Cntrl 1 ug
Amot 98 1 ug
Amot 98 1 ug
Amot 98 1 ug
Amot 98 1 ug
Amot 98 1 ug
Amot 98 1 ug
Amot 98 1 ug
Amot 98 1 ug
Amot 98 1 ug
Amot 98 1 ug
Amot 98 1 ug
Amot 98 1 ug
Amot 98 1 ug
Amot 98 1 ug
Amot 98 1 ug
Amot 98 1 ug
Amot 174 1 ug
Amot 174 1 ug
Amot 174 1 ug
Amot 174 1 ug
Amot 174 1 ug
Amot 174 1 ug
Amot 174 1 ug
Amot 174 1 ug
Amot 174 1 ug
Amot 174 1 ug
Amot 174 1 ug
Amot 174 1 ug
Amot 174 1 ug
Amot 174 1 ug
Amot 174 1 ug
Amot 174 1 ug
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Cq
16.66
16.09
15.98
16.23
15.81
15.86
15.95
15.81
19.97
20.03
20.10
20.11
17.54
17.41
17.53
17.45
16.29
16.09
16.08
16.97
15.93
15.69
15.94
15.79
19.73
19.76
19.77
19.75
17.22
17.05
17.05
16.95
16.39
16.36
16.22
16.24
15.74
15.84
15.96
15.92
20.29
20.33
20.46
20.34
17.66
17.85
17.72
17.68

Melt Temp. (℃)
89.50
89.50
89.50
89.50
85.50
85.00
85.00
85.50
84.00
84.00
84.00
84.00
86.00
86.00
86.00
86.00
89.50
89.50
89.50
89.50
85.00
85.00
85.00
85.00
84.00
84.00
84.00
84.00
86.00
86.00
86.00
86.00
89.50
89.50
89.50
89.50
85.00
85.00
85.00
85.00
84.00
84.00
84.00
84.00
86.00
86.50
86.50
86.00

Actin
Actin
Actin
Actin
GAPDH
GAPDH
GAPDH
GAPDH
Amot
Amot
Amot
Amot
PCNA
PCNA
PCNA
PCNA
Actin
Actin
Actin
Actin

Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
NTC
NTC
NTC
NTC

Amot 257 1 ug
Amot 257 1 ug
Amot 257 1 ug
Amot 257 1 ug
Amot 257 1 ug
Amot 257 1 ug
Amot 257 1 ug
Amot 257 1 ug
Amot 257 1 ug
Amot 257 1 ug
Amot 257 1 ug
Amot 257 1 ug
Amot 257 1 ug
Amot 257 1 ug
Amot 257 1 ug
Amot 257 1 ug
N/A
N/A
N/A
N/A
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15.72
15.79
15.86
15.60
15.47
15.54
15.67
15.38
19.40
19.48
19.47
19.48
17.06
17.06
17.17
17.03
37.71
39.51
36.52
38.63

89.50
89.50
89.50
89.50
85.50
85.00
85.00
85.00
84.00
84.00
84.00
84.00
86.00
86.50
86.50
86.50
None
None
None
None

the two target genes (Amot and PCNA) in cells transfected with the treatment CRISPR
constructs (Amot 98, Amot 174, and Amot 257). Normalized expression, or ∆∆Cq, is calculated
by first setting the expression of each target gene (Amot and PCNA) relative to the positive
controls (ß-actin and GAPDH) to 1 in the cells transfected with the Scrambled CRISPR control
plasmid. Then, the relative expression of the target genes is either higher or lower than 1 in those
cells transfected with the Amot 98, Amot 174, or Amot 257 treatment plasmids. The Bio-Rad
CFX Maestro software was used to generate the normalized expression of each target in the 1-µg
condition (Figure 4). From the normalized expression, it appeared that the expression of Amot
and PCNA was significantly less in the cells transfected with 1 µg of the Amot 174 construct
than in the cells transfected with the same concentration of the Scrambled CRISPR construct. In
those cells transfected with 1 µg of the Amot 98 construct, the expression of Amot and PCNA
actually appeared to be significantly higher than the expression within the control group. Finally,
in the cells transfected with 1 µg of the Amot 257 construct, the expression of Amot showed a
significant increase; PCNA expression, on the other hand, showed no significant increase or
decrease.
Quantitative PCR was also performed for the 2-µg condition. Identical to the design of 1µg condition, each cDNA sample from the cells transfected with 2 µg of DNA was targeted for
ß-actin, GAPDH, Amot, and PCNA. The CFX96 Real-Time System was used to generate the Cq
values for each particular target within the different cDNA samples (Table 4). For the Scrambled
CRISPR (CNTRL) samples, the mean Cq value for the ß-actin target was 33.89; the mean Cq
value for the GAPDH target was 21.32; the mean Cq value for the Amot target was 24.70; and
the mean Cq value for the PCNA target was 22.66. With the targets listed in the same order, the
mean Cq values for the Amot 98 samples were 23.05, 21.27, 24.31, and 22.80, respectively. The
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Figure 4: This figure depicts the normalized expression graph for the 1-µg condition. As
mentioned, the expression within the control was set to 1.0. The error bars represent standard
error of the mean. Significance was determined by a P-value less than 0.01.
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Table 4: Cq values and melt temperatures across the 2-µg condition
Target
Actin
Actin
Actin
Actin
GAPDH
GAPDH
GAPDH
GAPDH
Amot
Amot
Amot
Amot
PCNA
PCNA
PCNA
PCNA
Actin
Actin
Actin
Actin
GAPDH
GAPDH
GAPDH
GAPDH
Amot
Amot
Amot
Amot
PCNA
PCNA
PCNA
PCNA
Actin
Actin
Actin
Actin
GAPDH
GAPDH
GAPDH
GAPDH
Amot
Amot
Amot
Amot
PCNA
PCNA
PCNA
PCNA

Content
Pos Ctrl
Pos Ctrl
Pos Ctrl
Pos Ctrl
Pos Ctrl
Pos Ctrl
Pos Ctrl
Pos Ctrl
Pos Ctrl
Pos Ctrl
Pos Ctrl
Pos Ctrl
Pos Ctrl
Pos Ctrl
Pos Ctrl
Pos Ctrl
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn

Sample
Cntrl 2 ug
Cntrl 2 ug
Cntrl 2 ug
Cntrl 2 ug
Cntrl 2 ug
Cntrl 2 ug
Cntrl 2 ug
Cntrl 2 ug
Cntrl 2 ug
Cntrl 2 ug
Cntrl 2 ug
Cntrl 2 ug
Cntrl 2 ug
Cntrl 2 ug
Cntrl 2 ug
Cntrl 2 ug
Amot 98 2 ug
Amot 98 2 ug
Amot 98 2 ug
Amot 98 2 ug
Amot 98 2 ug
Amot 98 2 ug
Amot 98 2 ug
Amot 98 2 ug
Amot 98 2 ug
Amot 98 2 ug
Amot 98 2 ug
Amot 98 2 ug
Amot 98 2 ug
Amot 98 2 ug
Amot 98 2 ug
Amot 98 2 ug
Amot 174 2 ug
Amot 174 2 ug
Amot 174 2 ug
Amot 174 2 ug
Amot 174 2 ug
Amot 174 2 ug
Amot 174 2 ug
Amot 174 2 ug
Amot 174 2 ug
Amot 174 2 ug
Amot 174 2 ug
Amot 174 2 ug
Amot 174 2 ug
Amot 174 2 ug
Amot 174 2 ug
Amot 174 2 ug
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Cq
33.61
36.41
31.65
21.38
21.25
21.32
21.31
24.71
24.70
24.72
24.68
22.72
22.61
22.62
22.69
23.46
23.09
22.89
22.76
21.28
21.33
21.31
21.16
24.26
24.31
24.31
24.38
22.87
22.73
22.80
22.80
26.95
25.91
25.02
24.40
22.26
22.32
22.38
22.25
25.70
25.78
26.01
25.82
23.52
23.65
23.56
23.50

Melt Temp. (℃)
None
None
None
88.50
84.50
84.50
84.50
84.50
83.50
83.50
83.50
83.50
86.50
86.00
86.00
86.00
89.00
89.00
89.00
89.00
84.50
84.50
84.50
85.00
83.50
83.50
83.50
83.50
86.50
86.00
86.00
86.00
89.00
89.00
89.00
89.00
84.50
84.50
84.50
84.50
83.50
83.50
83.50
83.50
86.00
86.00
86.00
86.00

Actin
Actin
Actin
Actin
GAPDH
GAPDH
GAPDH
GAPDH
Amot
Amot
Amot
Amot
PCNA
PCNA
PCNA
PCNA
Actin
Actin
Actin
Actin

Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
NTC
NTC
NTC
NTC

Amot 257 2 ug
Amot 257 2 ug
Amot 257 2 ug
Amot 257 2 ug
Amot 257 2 ug
Amot 257 2 ug
Amot 257 2 ug
Amot 257 2 ug
Amot 257 2 ug
Amot 257 2 ug
Amot 257 2 ug
Amot 257 2 ug
Amot 257 2 ug
Amot 257 2 ug
Amot 257 2 ug
Amot 257 2 ug
N/A
N/A
N/A
N/A
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22.65
22.77
22.92
22.95
21.35
21.44
21.49
21.40
25.09
25.16
25.14
25.10
23.06
23.14
23.15
23.07
N/A
38.40
N/A
N/A

89.50
89.50
89.50
89.50
85.00
85.00
85.00
85.00
83.50
84.00
83.50
83.50
86.50
86.50
86.50
86.50
None
None
None
None

mean Cq values for the Amot 174 samples were determined to be 25.57, 22.30, 25.83, and 23.56.
For the Amot 257 samples, the mean Cq values were determined to be 22.82, 21.42, 25.12, and
23.10. Lastly, for the no-template control samples, the mean Cq was determined to be 38.40. The
melt temperature analysis of this 2-µg revealed data similar to that which was collected in the
preceding condition. For example, the melt temperature of each sample targeting ß-actin was
approximately 89℃; the melt temperature of each sample targeting GAPDH was approximately
85 ℃; the melt temperature of each sample targeting Amot was approximately 84 ℃; and the
melt temperature of each sample targeting PCNA was approximately 86 ℃ (Table 4). In the notemplate control samples, on the other hand, no melt temperature could be determined. As
mentioned earlier, the mean Cq values were essential to determining relative normalized
expression. The Bio-Rad CFX Maestro software was used to generate the normalized expression
graph for the 2-µg condition (Figure 5). From the normalized expression graph, it appeared that
there was a significant decrease in Amot and PCNA expression in cells treated with the Amot 98
construct relative to those cells treated with the control construct. A similar trend was seen in
those cells treated with the Amot 174 construct, as a significant decrease was seen in normalized
expression for both Amot and PCNA. Lastly, it appeared that there was also a significant
decrease in both Amot and PCNA expression in those cells treated with the Amot 257 construct.
Finally, qPCR was also performed for the 4-µg condition. Again, each cDNA sample
from those cells treated with 4 µg of DNA was targeted for ß-actin, GAPDH, Amot, and PCNA.
The Cq values of each target tested for in the different cDNA samples were determined using the
CFX96 Real-Time System (Table 5). For the CNTRL samples, the mean Cq value for the ß-actin
target was 19.48; the mean Cq value for the GAPDH target was 17.96; the mean Cq value for the
Amot target was 22.83; and the mean Cq value for the PCNA target was 19.53. With the targets
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Figure 5: This figure depicts the normalized expression graph for the 2-µg condition. As
mentioned, the expression within the control was set to 1.0. The error bars represent standard
error of the mean. Significance was determined by a P-value less than 0.01.
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Table 5: Cq values and melt temperatures across the 4-µg condition
Target
Actin
Actin
Actin
Actin
GAPDH
GAPDH
GAPDH
GAPDH
Amot
Amot
Amot
Amot
PCNA
PCNA
PCNA
PCNA
Actin
Actin
Actin
Actin
GAPDH
GAPDH
GAPDH
GAPDH
Amot
Amot
Amot
Amot
PCNA
PCNA
PCNA
PCNA
Actin
Actin
Actin
Actin
GAPDH
GAPDH
GAPDH
GAPDH
Amot
Amot
Amot
Amot
PCNA
PCNA
PCNA
PCNA

Content
Pos Ctrl
Pos Ctrl
Pos Ctrl
Pos Ctrl
Pos Ctrl
Pos Ctrl
Pos Ctrl
Pos Ctrl
Pos Ctrl
Pos Ctrl
Pos Ctrl
Pos Ctrl
Pos Ctrl
Pos Ctrl
Pos Ctrl
Pos Ctrl
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn

Sample
Cntrl 4ug
Cntrl 4ug
Cntrl 4ug
Cntrl 4ug
Cntrl 4ug
Cntrl 4ug
Cntrl 4ug
Cntrl 4ug
Cntrl 4ug
Cntrl 4ug
Cntrl 4ug
Cntrl 4ug
Cntrl 4ug
Cntrl 4ug
Cntrl 4ug
Cntrl 4ug
Amot 98 4ug
Amot 98 4ug
Amot 98 4ug
Amot 98 4ug
Amot 98 4ug
Amot 98 4ug
Amot 98 4ug
Amot 98 4ug
Amot 98 4ug
Amot 98 4ug
Amot 98 4ug
Amot 98 4ug
Amot 98 4ug
Amot 98 4ug
Amot 98 4ug
Amot 98 4ug
Amot 174 4ug
Amot 174 4ug
Amot 174 4ug
Amot 174 4ug
Amot 174 4ug
Amot 174 4ug
Amot 174 4ug
Amot 174 4ug
Amot 174 4ug
Amot 174 4ug
Amot 174 4ug
Amot 174 4ug
Amot 174 4ug
Amot 174 4ug
Amot 174 4ug
Amot 174 4ug
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Cq
19.73
19.44
19.40
19.35
17.94
17.98
17.96
17.95
22.80
22.87
22.88
22.77
19.54
19.44
19.49
19.63
16.97
16.58
16.41
16.29
16.13
16.03
16.10
16.07
20.55
20.40
20.34
20.41
17.77
17.64
17.61
17.75
18.90
18.89
18.34
18.57
17.76
17.79
17.66
17.67
22.70
22.68
22.76
22.76
19.72
19.97
20.02
-

Melt Temp. (℃)
89.00
89.00
89.00
89.00
85.50
85.00
85.00
85.00
84.00
84.00
84.00
84.00
86.50
86.50
86.50
86.50
89.00
89.00
89.00
89.00
85.00
85.00
85.00
85.00
84.00
84.00
84.00
84.00
86.50
86.50
86.50
86.50
89.00
89.00
89.00
89.00
85.50
85.50
85.50
85.00
84.00
84.00
84.00
84.00
86.50
86.50
86.50
None

Actin
Actin
Actin
Actin
GAPDH
GAPDH
GAPDH
GAPDH
Amot
Amot
Amot
Amot
PCNA
PCNA
PCNA
PCNA
Actin
Actin
Actin
Actin

Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
Unkn
NTC
NTC
NTC
NTC

Amot 257 4ug
Amot 257 4ug
Amot 257 4ug
Amot 257 4ug
Amot 257 4ug
Amot 257 4ug
Amot 257 4ug
Amot 257 4ug
Amot 257 4ug
Amot 257 4ug
Amot 257 4ug
Amot 257 4ug
Amot 257 4ug
Amot 257 4ug
Amot 257 4ug
Amot 257 4ug
N/A
N/A
N/A
N/A
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16.44
16.48
16.39
16.37
16.15
16.18
16.19
16.15
20.50
20.62
20.55
20.52
17.66
17.70
17.72
17.88
N/A
N/A
N/A
N/A

89.50
89.50
89.50
89.50
85.50
85.50
85.50
85.50
84.00
84.00
84.00
84.00
86.50
86.50
86.50
86.50
None
None
None
None

listed in the same order, the mean Cq values of the Amot 98 samples were 16.56, 16.08, 20.43,
and 17.69. The mean Cq values of the Amot 174 samples were 18.67, 17.72, 22.73, and 19.90.
Lastly, the mean Cq values of the Amot 257 samples were 16.42, 16.17, 20.55, and 17.74. The
no-template control samples did not yield any Cq values. In addition to the determination of the
Cq values for each target, melt temperature analysis was performed to analyze the amplified
targets (Table 5). Similar to the previous conditions, the melt temperature of each ß-actin gene
product was approximately 89 ℃. Additionally, the melt temperature of each GAPDH gene
product was approximately 85 ℃. Furthermore, the melt temperature of each Amot gene product
was determined to be approximately 84 ℃. Finally, the melt temperature of each PCNA gene
product was 86.5 ℃. In addition to failing to yield Cq values, the no-template control samples
did not provide any melt temperature values. Through the use of the Bio-Rad CFX Maestro
software once again, normalized expression of the two target genes was determined for each of
the treatment constructs (Figure 6). In the cells treated with 4 µg of the Amot 174 construct,
there appeared to be a significant decrease in the expression of Amot and in the expression of
PCNA relative to those cells treated with 4 µg of the Scrambled CRISPR control plasmid. In the
cells treated with 4 µg of the Amot 257 construct, there appeared to be a significant decrease in
the expression of both Amot and PCNA relative to the control. Finally, in the cells treated with 4
µg of the Amot 98 construct, there was no significant decrease or increase in the expression of
Amot. However, there was a significant decrease in the expression of PCNA in those cells
treated with 4 µg of the Amot 98 construct.
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Figure 6: This figure depicts the normalized expression graph for the 4-µg condition. As
mentioned, the expression within the control was set to 1.0. The error bars represent standard
error of the mean. Significance was determined by a P-value less than 0.01.
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Discussion
Although angiomotin was the main target of interest in the current study, proliferating
cell nuclear antigen (PCNA) was also targeted in order to determine if there are any potential
links between angiomotin expression and PCNA expression. Proliferating cell nuclear antigen is
considered to be a member of the DNA sliding clamp family of proteins, along with the ßsubunit of DNA polymerase III from E. coli. PCNA is considered to be a member of this protein
family due to the fact that PCNA can form a ring around DNA (Strzalka and Ziemienowicz
2011). PCNA is known to have a role in the processes of DNA replication, DNA repair, cell
cycle regulation, and even apoptosis. These roles were elucidated when it was discovered that
PCNA can bind DNA, cyclins, DNA polymerase, cyclin-dependent kinases, and even p21 (Maga
and Hübscher 2003). While it is known that PCNA can interact with all of the aforementioned
proteins, it is not yet known how the exact impact of PCNA is regulated. One study believes that
the varying binding affinities between PCNA and its substrates may contribute to its regulation,
so these binding affinities should be determined to elucidate the mechanisms of PCNA within the
cell (Maga and Hübscher 2003). The connection of PCNA to processes essential to the cell’s
survival, such as DNA replication and repair, is the primary reason why PCNA expression is
examined alongside Amot expression. In reducing the expression of Amot in tumorigenic cells, it
is hoped that these cells would show decreased cell viability. Therefore, if PCNA shows a
similar decrease in expression when Amot is silenced, then it is possible that Amot may be an
effective target for the treatment of cancer cells. This potential association is kept in mind
throughout the analysis of the data of the current study.
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The raw data of the 1-µg condition reveals that this part of the experiment was performed
with success. For example, for each target, the Cq values are all very precise. This precision
indicates that the pipetting of both the primer mixes and the cDNA samples into the 96-well plate
was performed effectively, avoiding the addition of different amounts of either the sample or the
primer mix to each well. Furthermore, the melt temperature analysis reveals that contamination
was avoided. There are two types of contamination: primer-dimers and genomic contamination.
Primer-dimers occur when the primers base-pair, and they are usually detected by a melt
temperature of about 77 ℃. Genomic contamination, on the other hand, occurs when
contamination is introduced from the external environment, and it is characterized by a melt
temperature of about 95 ℃. With the melt temperatures for each target being between 84 ℃ and
89 ℃, it is apparent that there was no contamination in the samples. Furthermore, the lack of Cq
values and melt temperatures for the no-template controls strengthen the overall accuracy of this
condition, for these are the results expected of no-template controls. Given both the accuracy and
precision of the experiment, the data can certainly be useful for making conclusions. Earlier it
was indicated that there was a significant decrease in Amot and PCNA expression in the cells
treated with 1 µg of the Amot 174 CRISPR construct. In those cells treated with 1 µg of Amot
257, however, the expression of Amot increased significantly, while the expression of PCNA had
no significant increase or decrease. Likewise, in those cells treated with 1 µg of the Amot 98
construct, there was a significant increase in Amot and in PCNA. It is strange that only the Amot
174 construct was successful at this concentration, but this difference could be caused by a few
factors. First, it is possible that the Amot 174 construct is simply more effective at silencing
Amot than the other two constructs. Additionally, the “increase” in Amot expression seemingly
caused by the Amot 98 and the Amot 257 constructs could have been due to the fact that the
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successfully edited cells died prior to RNA extraction. If Amot and PCNA expression are truly
intimately coordinated, then a decrease in Amot would likely correspond to a decrease in cell
viability and survivability. If the cells died before the RNA extraction, then the cells that were
present were likely those that were not successfully edited by the Amot 98 and Amot 257
constructs. This possibility must be considered prior to ruling out the other constructs for
subsequent studies.
Examination of the 2-µg data reveals a part of the experiment that may not have been
performed with the same level of precision and accuracy as the previous condition. In each
quantitative polymerase chain reaction that was performed, two different housekeeping genes
were targeted to determine the fidelity of the whole reaction. Housekeeping genes, such as those
that code for ß-actin and GAPDH, are considered to be constitutively active; therefore, the Cq
values for these targets should always be relatively low. However, when targeting ß-actin in the
2 µg CNTRL samples, the Cq values were either above 30 or unavailable. Cq values above 30
indicate that the target was present in very low quantities to begin with or that there was really no
target present at all. The high Cq values for ß-actin in the 2 µg CNTRL samples could have been
due to a lack of effectively mixing the primer mix, or they could have been caused by improper
pipetting. Regardless, the abnormal Cq values for this housekeeping gene could certainly skew
the normalized expression, for normalized expression is determined by comparing the expression
of the target gene to the expression of a positive control. Therefore, conclusions drawn from the
2-µg condition may not be as useful as those drawn from conditions that were performed with
greater experimental precision and accuracy. Despite the abnormal Cq values for ß-actin in the
CNTRL 2 µg samples, there was no contamination present throughout this condition: there were
no melt temperatures corresponding to either genomic contamination or primer-dimers.
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According to the normalized expression graph from the 2-µg condition (Figure 5), there was a
significant decrease in the expression of Amot and PCNA in cells transfected with the Amot 98
construct, the Amot 174 construct, and the Amot 257 construct. However, as mentioned above,
these results should not be used to draw meaningful conclusions. Instead, repetition of this
particular condition would be needed to verify if each construct really caused significant
decreases in Amot expression and PCNA expression.
Analysis of the data generated from the 4-µg condition reveals another part of the
experiment that was performed with precision and accuracy. For example, for each set of targets,
the Cq values were all very close. As in the 1-µg condition, this precision demonstrates effective
pipetting throughout the preparation of the 96-well plate. In addition, the Cq values of the
housekeeping genes are predictably low, demonstrating that the positive control samples could
be used as an effective source of comparison for the expression of Amot and PCNA.
Furthermore, the melt temperature analysis conveys a lack of contamination: there are no melt
temperatures indicative of either primer-dimers or genomic contamination. Finally, the lack of
Cq values and melt temperatures from the no-template control samples emphasizes the avoidance
of contamination in this condition. From the normalized expression graph (Figure 6), it is
apparent that there was a significant decrease in expression of both Amot and PCNA in those
cells treated with either 4 µg of the Amot 174 construct or 4 µg of the Amot 257 construct.
However, the cells treated with the Amot 98 construct demonstrated a significant decrease in
PCNA expression and no significant change in Amot expression. Similar to the evaluation of the
1-µg condition, it is possible that the lack of reduction in Amot expression seen in cells treated
with 4 µg of Amot 98 could be due to the fact that the edited cells died. Conversely, it is also
possible that the Amot 98 construct is simply not as effective as the other constructs at silencing
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Amot. Again, repetition is essential to determine the efficacy of each construct. For example,
even though treatment with 4 µg of Amot 174 or 4 µg Amot 257 seems to effectively attenuate
Amot expression and cause a concurrent decrease in PCNA expression, repetition is still needed
to verify the association between Amot and PCNA and to determine if these constructs are truly
effective at this concentration.
Overall, it does appear that there is an association between Amot expression and PCNA
expression. For example, reductions in Amot expression were typically mirrored by reductions in
PCNA expression, while increases in Amot expression were also mirrored by increases in PCNA
expression. However, it is important to remember that this association does not necessarily
indicate a direct connection between the two targets. It was mentioned that PCNA binds to many
proteins involved in many different cellular processes, so it is likely that the association is a
complicated one. Furthermore, the current study revealed that the Amot 174 CRISPR construct
was the most effective construct at silencing Amot across all conditions. Though the results of
the 2-µg condition are not entirely conclusive, the 1-µg and 4-µg conditions reveal a significant
decrease in both Amot expression and PCNA expression in those cells treated with the Amot 174
construct. Therefore, future studies should include repetition of the current study in order to
verify the efficacy of the Amot 174 construct at reducing Amot expression and to determine
which concentration of this construct is most effective. End-point PCR could be performed in
conjunction with qPCR in order to confirm that angiomotin was successfully edited.
Furthermore, western blots should be performed to determine if the significant reductions in
Amot and PCNA gene expression can be confirmed by significant reductions in the protein
levels within treated cells. Additionally, given the association between Amot and PCNA
expression, cell viability assays should be performed to examine if silencing Amot significantly
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reduces cell viability. Lastly, to biochemically verify reduction in cell viability, it would be
worthwhile to target expression of various pro-apoptotic factors alongside Amot and PCNA
expression. Given the numerous connections between angiomotin and breast cancer pathology,
further studies are certainly justified to elucidate whether or not angiomotin could serve as an
effective target for breast cancer treatment.
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